Premium
Cell‐based assay for screening 11 β ‐hydroxysteroid dehydrogenase inhibitors using liquid chromatography/tandem mass spectrometry detection
Author(s) -
Xu Rongda,
Sang BiChing,
Navre Marc,
Kassel Daniel B.
Publication year - 2006
Publication title -
rapid communications in mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.528
H-Index - 136
eISSN - 1097-0231
pISSN - 0951-4198
DOI - 10.1002/rcm.2484
Subject(s) - chemistry , cortisone , 11β hydroxysteroid dehydrogenase type 1 , dehydrogenase , chromatography , tandem mass spectrometry , mass spectrometry , in vivo , enzyme , steroid , liquid chromatography–mass spectrometry , reductase , biochemistry , endocrinology , hormone , medicine , microbiology and biotechnology , biology
Cortisol is an important glucocorticoid that regulates many physiological pathways by activating various intracellular receptors. The type 1 isozyme of 11 β ‐hydroxysteroid dehydrogenase (11 β ‐HSD1) functions in vivo predominantly as a reductase by converting cortisone into cortisol. A high‐throughput liquid chromatography/tandem mass spectrometry (LC/MS/MS) method has been developed to screen for inhibitors of 11 β ‐HSD1 by monitoring cortisol and cortisone simultaneously. The injection cycle time can be as fast as 1 min/sample, making it amenable to the analysis of large numbers of the cell‐assay samples in the screening of 11 β ‐HSD inhibitors. The reductase and dehydrogenase activities of 11 β ‐HSD1 are assessed separately. Copyright © 2006 John Wiley & Sons, Ltd.